Published in Nat Med on October 27, 2013
Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth. JAMA (2015) 2.02
The landscape and therapeutic relevance of cancer-associated transcript fusions. Oncogene (2014) 1.49
ALK inhibitors in non-small cell lung cancer: crizotinib and beyond. Clin Adv Hematol Oncol (2014) 1.48
What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC). Ann Oncol (2016) 1.21
TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov (2014) 1.19
Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nat Genet (2016) 1.16
Molecular pathways and therapeutic targets in lung cancer. Oncotarget (2014) 1.16
An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101. Cancer Discov (2015) 1.13
Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer. Transl Lung Cancer Res (2015) 1.07
Targeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor. Semin Oncol (2013) 1.03
Prognostic and predictive biomarkers in lung cancer. A review. Virchows Arch (2014) 1.00
Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol (2015) 0.97
Lung cancer in the era of precision medicine. Clin Cancer Res (2015) 0.96
Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK. Cancers (Basel) (2015) 0.93
Regulation of EGFR nanocluster formation by ionic protein-lipid interaction. Cell Res (2014) 0.93
FACTERA: a practical method for the discovery of genomic rearrangements at breakpoint resolution. Bioinformatics (2014) 0.93
NTRK1 fusion in glioblastoma multiforme. PLoS One (2014) 0.91
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). Cancer Discov (2017) 0.90
Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer. Cancers (Basel) (2015) 0.90
Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer. J Natl Cancer Inst (2015) 0.90
Investigation of neurotrophic tyrosine kinase receptor 1 fusions and neurotrophic tyrosine kinase receptor family expression in non-small-cell lung cancer and sensitivity to AZD7451 in vitro. Mol Clin Oncol (2014) 0.88
Gene aberrations for precision medicine against lung adenocarcinoma. Cancer Sci (2016) 0.88
NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open (2016) 0.87
Promising Targets and Current Clinical Trials in Metastatic Non-Squamous NSCLC. Front Oncol (2014) 0.87
ALK inhibitors in non-small cell lung cancer: the latest evidence and developments. Ther Adv Med Oncol (2016) 0.86
Recurrent NTRK1 Gene Fusions Define a Novel Subset of Locally Aggressive Lipofibromatosis-like Neural Tumors. Am J Surg Pathol (2016) 0.85
MicroRNA In Lung Cancer: Novel Biomarkers and Potential Tools for Treatment. J Clin Med (2016) 0.85
Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer. J Thorac Oncol (2015) 0.84
Neurotrophic tyrosine kinase receptor 1 is a direct transcriptional and epigenetic target of IL-13 involved in allergic inflammation. Mucosal Immunol (2014) 0.83
TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts. Cancer Chemother Pharmacol (2014) 0.82
Tyrosine receptor kinase B is a drug target in astrocytomas. Neuro Oncol (2016) 0.82
Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer. Oncotarget (2016) 0.81
Epigenetic mechanisms underlying the pathogenesis of neurogenetic diseases. Neurotherapeutics (2014) 0.80
Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma. Expert Rev Mol Diagn (2016) 0.80
Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC. Front Oncol (2016) 0.79
Update in Lung Cancer 2014. Am J Respir Crit Care Med (2015) 0.79
Genomic aberrations in spitzoid melanocytic tumours and their implications for diagnosis, prognosis and therapy. Pathology (2016) 0.79
The EML4-ALK oncogene: targeting an essential growth driver in human cancer. Proc Jpn Acad Ser B Phys Biol Sci (2015) 0.79
Genomically driven precision medicine to improve outcomes in anaplastic thyroid cancer. J Oncol (2014) 0.78
The minority report: targeting the rare oncogenes in NSCLC. Curr Treat Options Oncol (2014) 0.78
NTRK1 fusions for the therapeutic intervention of Korean patients with colon cancer. Oncotarget (2016) 0.77
Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy. Ther Adv Med Oncol (2015) 0.76
(R)-2-Phenylpyrrolidine Substituted Imidazopyridazines: A New Class of Potent and Selective Pan-TRK Inhibitors. ACS Med Chem Lett (2015) 0.76
NGF-induced TrkA/CD44 association is involved in tumor aggressiveness and resistance to lestaurtinib. Oncotarget (2015) 0.76
OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations. Oncotarget (2016) 0.76
Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model. Cancer Lett (2016) 0.76
Identification of pyrazine-based TrkA inhibitors: design, synthesis, evaluation, and computational modeling studies. Medchemcomm (2014) 0.75
The Hedgehog Signaling Networks in Lung Cancer: The Mechanisms and Roles in Tumor Progression and Implications for Cancer Therapy. Biomed Res Int (2016) 0.75
Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer. Clin Cancer Res (2016) 0.75
Lung Cancer Biomarkers. Hematol Oncol Clin North Am (2017) 0.75
Tracking Down Response and Resistance to TRK Inhibitors. Cancer Discov (2016) 0.75
Identification of TRA2B-DNAH5 fusion as a novel oncogenic driver in human lung squamous cell carcinoma. Cell Res (2016) 0.75
[Morphological and genetic aspects of Spitz tumors]. Pathologe (2015) 0.75
Something Old, Something New, Something Borrowed, Something Fused: Novel EGFR Rearrangements in Lung Adenocarcinomas. Cancer Discov (2016) 0.75
Tyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical Implications. Dis Markers (2016) 0.75
Lung cancer: drug-sensitivity--time for a rearrangement? Nat Rev Clin Oncol (2013) 0.75
Alterations in genes other than EGFR/ALK/ROS1 in non-small cell lung cancer: trials and treatment options. Cancer Biol Med (2016) 0.75
Breaking down RET breakpoints in lung adenocarcinoma. J Thorac Oncol (2014) 0.75
Clinicopathological significance of p14(ARF) expression in lung cancer: a meta-analysis. Onco Targets Ther (2017) 0.75
Kinase Gene Fusions in Defined Subsets of Melanoma. Pigment Cell Melanoma Res (2016) 0.75
Targeted next-generation sequencing of dedifferentiated chondrosarcoma in the skull base reveals combined TP53 and PTEN mutations with increased proliferation index, an implication for pathogenesis. Oncotarget (2016) 0.75
Fusion gene and splice variant analyses in liquid biopsies of lung cancer patients. Transl Lung Cancer Res (2016) 0.75
Molecular Testing of Lung Cancers. J Pathol Transl Med (2017) 0.75
Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance. Nat Rev Clin Oncol (2017) 0.75
Identification and characterization of a novel SCYL3-NTRK1 rearrangement in a colorectal cancer patient. Oncotarget (2017) 0.75
EGFR mediates responses to small molecule drugs targeting oncogenic fusion kinases. Cancer Res (2017) 0.75
Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy. Surg Today (2017) 0.75
Lung cancer as a paradigm for precision oncology in solid tumours. Virchows Arch (2017) 0.75
The Sequence Alignment/Map format and SAMtools. Bioinformatics (2009) 232.39
The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res (2010) 97.51
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med (2009) 46.35
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature (2007) 37.09
TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol (2013) 32.42
Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. Nat Biotechnol (2009) 27.17
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell (2007) 17.98
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med (2013) 14.78
Integrative analysis of the melanoma transcriptome. Genome Res (2010) 8.46
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature (2009) 7.05
Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med (2012) 6.77
RET, ROS1 and ALK fusions in lung cancer. Nat Med (2012) 6.76
Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res (2012) 6.23
A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences. Nature (1986) 5.88
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet (2012) 5.28
KIF5B-RET fusions in lung adenocarcinoma. Nat Med (2012) 4.38
A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res (2011) 4.22
A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res (2011) 4.15
The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res (2012) 3.80
Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov (2013) 3.64
Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med (2013) 3.42
Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov (2013) 3.13
Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem (2011) 2.97
Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells. Mol Pharmacol (2008) 2.71
Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin Cancer Res (2012) 2.66
Trk receptors use redundant signal transduction pathways involving SHC and PLC-gamma 1 to mediate NGF responses. Neuron (1994) 2.44
Molecular pathways: ROS1 fusion proteins in cancer. Clin Cancer Res (2013) 1.94
Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels. Clin Cancer Res (2006) 1.82
RET and NTRK1 proto-oncogenes in human diseases. J Cell Physiol (2003) 1.55
Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing. J Pathol (2013) 1.38
Myosin phosphatase-Rho interacting protein. A new member of the myosin phosphatase complex that directly binds RhoA. J Biol Chem (2003) 1.28
Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555). Cancer Res (1999) 1.19
Accessory molecules for MHC class II peptide loading. Curr Opin Immunol (2000) 1.14
Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models. Front Pharmacol (2013) 0.93